PlasmaSelect AG / Miscellaneous 29.08.2008 Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- The Board of Management of TheraSelect GmbH, a wholly owned subsidiary of PlasmaSelect AG, informed the companys works council today of its decision to close the production facility at Marburg in the second quarter of the next fiscal year. Production of Haemaccel® for the Indian Piramal Healthcare Group will be discontinued at that time. Bottelpack production operations in Marburg will be transferred to a contract producer from February 2009. These measures are aimed at avoiding the ongoing losses made by the Marburg plant. Writeoffs generated by the measures were largely taken into consideration in the last annual accounts. In addition, negative one-off effects from the closure will be considered in the results of the current fiscal year. DGAP 29.08.2008 --------------------------------------------------------------------------- Language: English Issuer: PlasmaSelect AG Pettenkoferstraße 22 80336 München Deutschland Phone: +49 (0)89 810 29-0 Fax: +49 (0)89 810 29-111 E-mail: info@plasmaselect.de Internet: www.plasmaselect.de ISIN: DE0005471809 WKN: 547180 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Stuttgart, München, Hamburg, Düsseldorf End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: PlasmaSelect AG: Closure of Marburg plant
| Source: EQS Group AG